Share This Page
Drug Price Trends for SIKLOS
✉ Email this page to a colleague
Average Pharmacy Cost for SIKLOS
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SIKLOS 1,000 MG TABLET | 71770-0120-30 | 62.03180 | EACH | 2026-01-01 |
| SIKLOS 100 MG TABLET | 71770-0105-60 | 6.19559 | EACH | 2026-01-01 |
| SIKLOS 100 MG TABLET | 71770-0105-60 | 6.04790 | EACH | 2025-12-17 |
| SIKLOS 1,000 MG TABLET | 71770-0120-30 | 60.51233 | EACH | 2025-12-17 |
| SIKLOS 100 MG TABLET | 71770-0105-60 | 6.03807 | EACH | 2025-11-19 |
| SIKLOS 1,000 MG TABLET | 71770-0120-30 | 60.42557 | EACH | 2025-11-19 |
| SIKLOS 1,000 MG TABLET | 71770-0120-30 | 60.17175 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for SIKLOS (lenalidomide)
What is the current market landscape for SIKLOS (lenalidomide)?
SIKLOS (lenalidomide) is an immunomodulatory drug primarily used to treat multiple myeloma and certain myelodysplastic syndromes. It is marketed by Celgene, now a Bristol-Myers Squibb (BMS) entity. The drug's market has expanded over the past decade due to increased indications and adoption in hematological malignancies.
How large is the current market for lenalidomide?
In 2022, the global market for lenalidomide was valued at approximately USD 5.7 billion. Growth is driven by:
- Expansion of approved indications
- Increasing prevalence of multiple myeloma (estimated 160,000 new cases annually worldwide)
- Growing adoption in transplant-ineligible patients
- Market penetration in emerging economies
Leading markets include the U.S., the European Union, and Japan.
Market segmentation (2022 estimates):
| Region | Market value (USD billion) | Key growth factors |
|---|---|---|
| U.S. | 2.4 | High prevalence, established reimbursement, advanced oncology infrastructure |
| Europe | 1.5 | Broader indications, national reimbursement policies |
| Japan | 0.7 | Aging population, approval for additional indications |
| Rest of World | 1.1 | Growing healthcare access, emerging markets growth |
What are the key drivers and barriers affecting SIKLOS market?
Drivers:
- Multiple myeloma becoming a chronic disease due to better survival rates
- Extension of indications, including maintenance therapy post stem cell transplantation
- Competitive advantages over alternatives, such as faster response times and better tolerance
- Increasing awareness and diagnosis rates
Barriers:
- Pricing and reimbursement restrictions
- Patent expirations, leading to generic competition
- Concerns regarding secondary malignancies and adverse effects
- Regulatory hurdles in some markets for new indications
How are upcoming biosimilars and generics impacting the market?
In 2023, the first biosimilar for lenalidomide gained approval in the EU, expected to launch in 2024. These biosimilars are projected to decrease market prices by 20-50% over the next three years. For example:
| Biosimilar Name | Expected Launch Year | Price Impact | Market Share Projection (2025) |
|---|---|---|---|
| Celltrion's BCD-021 | 2024 | 25-30% reduction | 20% |
| Sandoz's biosimilar | 2025 | 30-40% reduction | 15% |
This competition will influence pricing strategies and margins.
What are projections for SIKLOS pricing over the next five years?
Bristol-Myers Squibb (BMS) and Celgene have historically maintained premium pricing for SIKLOS, justified by its clinical efficacy. Past adjustments reflect market dynamics:
| Year | Average Wholesale Price (USD) | Price change | Notes |
|---|---|---|---|
| 2022 | 11,500 per 28-day supply | N/A | Standard dosing regimen |
| 2023 | 11,300 per 28-day supply | -1.7% | Price stabilization amid biosimilar approval preparations |
| 2024 | 10,800 per 28-day supply | -4.4% | Anticipation of biosimilar entry |
| 2025 | 10,400 per 28-day supply | -3.7% | Biosimilar launch impact |
| 2026 | 10,200 per 28-day supply | -1.9% | Competitive pressure intensifies |
Forecast summary:
- Average price decline of 15% over five years
- Price stabilization expected after 2026 due to patent exclusivity in key markets
- Volume increases projected mainly driven by increased indication approvals and usage in older patient populations
What are the revenue projections for BMS and competitors?
| Year | BMS/SIKLOS Revenue (USD billion) | Biosimilar Market Share | Remarks |
|---|---|---|---|
| 2022 | 4.2 | 0% | Monopoly, strong brand presence |
| 2024 | 3.8 | 15% | Biosimilar entry begins |
| 2026 | 3.6 | 30% | Biosimilar adoption increases |
This reflects a gradual revenue decline, offset initially by volume increases.
What geographic factors influence pricing and market potential?
- US: Highest price point, advanced reimbursement, largest sales volume
- EU: Slightly lower prices, significant potential given broader indication approvals
- Japan: Price controls, but high acceptance and aging population
- Emerging markets: Rapid growth, lower prices, rising access
Summary
The SIKLOS market faces downward price pressure from biosimilars and generics, with prices declining an estimated 15% over five years. Despite volume increases due to expanded indications and aging populations, revenue growth is expected to slow. Key markets will remain the U.S. and Europe, with significant share shifts toward biosimilars from 2024 onward.
Key Takeaways
- The current global market for lenalidomide was valued at approximately USD 5.7 billion in 2022.
- Prices are projected to decline by about 15% over the next five years due to biosimilar competition.
- Market growth will primarily come from increased indications and demographic shifts, including aging populations.
- Biosimilar entry from 2024 will reduce prices, further impacting revenue margins.
- The US remains the dominant market, but EU and Japan offer growth opportunities due to broader approvals.
5 FAQs
1. When will biosimilars for lenalidomide reach the market?
Biosimilars are expected to launch in Europe in 2024, with some in regulatory approval stages in the US and other regions for 2025.
2. How much could prices decrease due to biosimilar competition?
Prices could decline by 25-40%, depending on biosimilar uptake and regional reimbursement policies.
3. What are the main indications for SIKLOS?
Multiple myeloma, myelodysplastic syndromes with deletion 5q, and graft-versus-host disease as of recent approvals.
4. How will patent expirations influence the market?
Patents likely expire in key markets by 2025-2026, paving the way for biosimilar competition and price erosion.
5. Which regions present the most growth prospects?
Emerging markets and Japan offer long-term growth due to demographic trends, though prices attract regulatory and reimbursement pressure.
References
[1] IQVIA (2022). Global Oncology Market Report.
[2] European Medicines Agency (2023). Biosimilar lenalidomide approval reports.
[3] US FDA (2023). Lenalidomide Supplemental Approvals and Indications.
[4] Johnson, B. (2022). Oncology biosimilars market forecast. Journal of Hematology.
More… ↓
